Pfizer Inc. (PFE)
Pfizer vs. J&J: Comparing Growth, Patent Risks and Valuation
J&J's diversified portfolio, new drug launches and sales growth give it an edge despite Pfizer's cheaper valuation and higher yield.
Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know
Pfizer (PFE) closed the most recent trading day at $28.1, moving 1.47% from the previous trading session.
Pfizer: Growth Portfolio And Cost Cuts Support A Buy Through The LOE Trough
Pfizer is rated a Buy, with a compelling risk-reward profile despite near-term COVID normalization and patent expiry headwinds. PFE's new and acquired products are delivering strong double-digit growth, helping offset losses from COVID and the upcoming loss of exclusivity events. Cost-restructuring initiatives targeting $9.7 billion in savings by 2029 should cushion earnings and support margin resilience through the LOE-heavy period.
Pfizer: Buy Before The Street Catches Up To Its Own Numbers
Pfizer is rated buy, not for deep value, but due to a disconnect between management's bullish long-term growth guidance and a flat consensus earnings curve. Consensus models a permanent post-2026 revenue/EPS decline, but PFE's $13B product base is compounding at 20%+, and the Vyndamax settlement secures $2–3B annual revenue through 2031. Management guides to high single-digit revenue CAGR from 2028 to 2033, implying 2033 revenue of $21–26B above even the Street's highest estimate.
Pfizer: Poised For Gains With A New Drug Pipeline And Cost-Cutting Plans
Pfizer Inc. faces a significant loss of exclusivity wall, but the biopharma has a new drug pipeline and cost-cutting plans to cover most of the sales hits. PFE guided 2026 revenues to $61.5B, with COVID-19 revenues now minimal and high single-digit growth projected starting in 2029. The company has another major cost reduction plan for savings of up to $4B to offset most gross profit losses from LoEs, supporting stable EPS near $2.90 through 2028.
Eli Lilly Vs. Pfizer in 2027: One Is a Much Better Place to Park Your Pharmaceutical Capital Next Year
Lilly and Pfizer both reported recent quarters that turned heads for opposite reasons, and heading into 2027 only one of them deserves your pharmaceutical capital. The answer depends on a trade-off most investors get wrong.
3 Dividend Stocks Trading Cheap Enough to Buy Meaningful Stakes for Under $1,000
AT&T, Verizon, and Pfizer all trade under $50 a share, but a low entry price and genuine value are two very different things, and only one of these three high-yield names carries a coverage story that should make income investors
Pfizer's Dividend Yield Is Enormous. But Is the Payout Still Growing?
Pfizer has raised its dividend every year for over a decade, then something changed. Before you count on that 6% yield, find out what the payout's own behavior is quietly signaling about the company's financial confidence.
Is Trending Stock Pfizer Inc. (PFE) a Buy Now?
Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.
Pfizer Says Major Headwinds Are Easing as Pipeline, Obesity Plans Take Center Stage
Pfizer NYSE: PFE Chairman and Chief Executive Officer Albert Bourla said the drugmaker has addressed several major headwinds that weighed on investor attention, including policy uncertainty, declining COVID-19-related demand and upcoming losses of exclusivity for certain products.
Can Pfizer Overcome Its COVID and Patent Cliff Headwinds?
PFE faces COVID revenue declines and a patent cliff, but new products, acquisitions and a strong pipeline could fuel growth from 2029.
Pfizer's 6% Yield Masks a Fragile Dividend Story
Pfizer's payout looks like a safe harbor in a rough market, but the patent clock is ticking and the balance sheet leaves almost no room for error.
